Trial result ·
Role of magnesium as a protective agent in cisplatin-induced nephrotoxicity in head and neck cancer.
Written based on 1 research study on PubMed, searched on 6 Nov 2026.
What was studied
This trial tested magnesium sulfate (MgSO4) as a shield against kidney injury from cisplatin. People had newly diagnosed head and neck squamous cell cancer. They were randomly put into 4 groups of 25. The control group got cisplatin 40 mg/m2 for 7 cycles. The other groups got the same cisplatin plus magnesium by infusion. The doses were 1 g, 2 g, or 3 g. All groups also had radiotherapy.
What they found
Groups that got magnesium had lower urine KIM-1 and NGAL than the control group. After cycle 7, serum sFasL and MDA were lower in the 3 g group. The comparison was with the control group. The abstract also compares the 3 g group with lower doses.
What it means for patients
The authors conclude that magnesium can serve as a shield against this kidney injury. They say it lowered kidney injury markers at different doses compared with cisplatin alone. They also say magnesium may help quality of life in these patients.
Why it is not certain yet
The abstract reports blood and urine markers, not kidney failure. It gives no quality of life results. Each group had only 25 people. The abstract does not say how long people were followed.
Source
Role of magnesium as a protective agent in cisplatin-induced nephrotoxicity in head and neck cancer.
PubMed · PMID 42969995We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Head and neck cancer publications